Exane Derivatives’s Clovis Oncology, Inc. CLVS Stock Holding History

Exane Derivatives’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$299	Hold	166	–	–	﹤0.01%	641
2022 Q1	$335	Hold	166	–	–	﹤0.01%	913
2021 Q4	$450	Hold	166	–	–	﹤0.01%	780
2021 Q3	$740	Hold	166	–	–	﹤0.01%	896
2021 Q2	$876	Hold	166	–	–	﹤0.01%	890
2021 Q1	$1.17K	Hold	166	–	–	﹤0.01%	717
2020 Q4	$797	Hold	166	–	–	﹤0.01%	698
2020 Q3	$968	Hold	166	–	–	﹤0.01%	621
2020 Q2	$1.12K	Hold	166	–	–	﹤0.01%	546
2020 Q1	$1.06K	Sell	166 -1,934	-92%	-$15.5K	﹤0.01%	544
2019 Q4	$19.8K	Hold	2,100	–	–	﹤0.01%	393
2019 Q3	$8.25K	Hold	2,100	–	–	﹤0.01%	440
2019 Q2	$31.2K	Hold	2,100	–	–	0.01%	412
2019 Q1	$52.1K	Hold	2,100	–	–	0.01%	336
2018 Q4	$37.7K	Hold	2,100	–	–	0.01%	390
2018 Q3	$61.7K	Hold	2,100	–	–	0.01%	361
2018 Q2	$95.4K	Buy	+2,100	New	+$102K	0.02%	339

Other funds holding CLVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Exane Derivatives's CLVS Position: Q2 2022 in Review

Exane Derivatives held its Clovis Oncology, Inc. (CLVS) position steady in Q2 2022 at 166 shares worth $299. The position accounts for ﹤0.01% of the portfolio, ranked #641.

Exane Derivatives first reported a position in CLVS in Q2 2018 and has held it in 17 quarters since. The position peaked at $95.4K in Q2 2018. 115 funds tracked by Wall St. Rank hold CLVS as of Q2 2022.

Exane Derivatives held 166 shares of Clovis Oncology, Inc. worth $299 as of Q2 2022.
Exane Derivatives left its Clovis Oncology, Inc. share count unchanged in Q2 2022.
Clovis Oncology, Inc. made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #641 holding.
Exane Derivatives first reported a position in Clovis Oncology, Inc. in Q2 2018 and has held it in 17 quarters since.
Exane Derivatives's Clovis Oncology, Inc. position peaked at $95.4K in Q2 2018.
115 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.